


## BGG463

|                           |  |       |         |
|---------------------------|--|-------|---------|
| <b>Cat. No.:</b>          | HY-100600  |       |         |
| <b>CAS No.:</b>           | 890129-26-7  |       |         |
| <b>Molecular Formula:</b> | C <sub>30</sub> H <sub>29</sub> F <sub>3</sub> N <sub>6</sub> O <sub>3</sub> |       |         |
| <b>Molecular Weight:</b>  | 578.58   |       |         |
| <b>Target:</b>            | CDK  |       |         |
| <b>Pathway:</b>           | Cell Cycle/DNA Damage  |       |         |
| <b>Storage:</b>           | Powder   | -20°C | 3 years |
|                           |  | 4°C   | 2 years |
|                           | In solvent   | -80°C | 2 years |
|                           |  | -20°C | 1 year  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 125 mg/mL (216.05 mM)  
 \* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Solvent Concentration | Mass      |           |            |
|---------------------------|-----------------------|-----------|-----------|------------|
|                           |                       | 1 mg      | 5 mg      | 10 mg      |
|                           | 1 mM                  | 1.7284 mL | 8.6418 mL | 17.2837 mL |
|                           | 5 mM                  | 0.3457 mL | 1.7284 mL | 3.4567 mL  |
|                           | 10 mM                 | 0.1728 mL | 0.8642 mL | 1.7284 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.08 mg/mL (3.60 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.08 mg/mL (3.60 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.08 mg/mL (3.60 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

BGG463 (K03859) is an orally active type II CDK2 inhibitor<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

CDK2

#### In Vitro

BGG463 potently inhibits T315I BCR-ABL autophosphorylation and shows good oral efficacy in mouse models of CML<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Alexander LT, et al. Type II Inhibitors Targeting CDK2. ACS Chem Biol. 2015 Sep 18;10(9):2116-25.
- [2]. Jones K, et al. Cancer Drug Discovery 2010: from molecules to medicine. Expert Rev Clin Pharmacol. 2010 Sep;3(5):613-5.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA